Curis Lifesciences share news and announcements
NSE: CURISPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹185.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹143 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Jul 2026
- 20.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 Jul 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Nov 2025
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 7 Jul 2026
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 Jul 2026
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,000100.0% delivered
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Curis Lifesciences half-yearly results
The board met on 30 May 2026 to consider financial results
Notice filed 26 May 2026
Curis Lifesciences annual reports, presentations and earnings calls
The company's own documents, latest first.Curis Lifesciences financials, year by year
Annual reports1
Investor presentations1
- Investor Presentation (opens in a new tab)11 Mar 2026
Earnings calls4
- Transcript (opens in a new tab)29 Jan 2026
- Link of Recording (opens in a new tab)22 Jan 2026
- Transcript (opens in a new tab)9 Jan 2026
- Link of Recording (opens in a new tab)4 Jan 2026
Curis Lifesciences share news and announcements
40 announcements, routine notices left out, newest first.
Sep 2026
7 Sep · Board meeting
3 Sep · Management
Aug 2026
Jul 2026
3 Jul · Management
3 Jul · Management
Jun 2026
May 2026
Mar 2026
31 Mar · Management
30 Mar · Business
2 Mar · Analysts
Feb 2026
24 Feb · Analysts
Jan 2026
13 Jan · Analysts
Dec 2025
31 Dec · Analysts
31 Dec · Analysts
25 Dec · Business
5 Dec · Board meeting
Nov 2025
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 4 Sep 2026Board or managers changedup 4.31%+4.3 pts vs Nifty 500market median 0.0% · five sessions +43.9% (+45.2 pts vs Nifty 500) · volume 3.0× usual · The announcement (opens in a new tab)
- 6 Jul 2026Board or managers changedup 0.90%+0.3 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+2.6 pts vs Nifty 500) · volume 0.4× usual · The announcement (opens in a new tab)
- 1 Apr 2026Board or managers changedup 7.48%+5.5 pts vs Nifty 500market median 0.0% · five sessions +9.5% (+1.6 pts vs Nifty 500) · volume 0.2× usual · The announcement (opens in a new tab)
Curis Lifesciences results filing dates and deadlines
Listed companies must file half-yearly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Plant in use, after depreciation | At Mar 2026 | Standalone | 10.78 | 12.10 | +12.3% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |
| Cash and cash equivalents | At Mar 2026 | Standalone | 3.17 | 3.17 | 0.0% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |
| Capital spending | Year to Mar 2026 | Standalone | 1.80 | 1.80 | 0.0% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |
| Cash from investing | Year to Mar 2026 | Standalone | −1.59 | −1.59 | 0.0% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |
| Net change in cash, before currency effects | Year to Mar 2026 | Standalone | 2.86 | 2.86 | 0.0% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |
| Net change in cash | Year to Mar 2026 | Standalone | 2.86 | 2.86 | 0.0% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |
| Cash at the end of the period | At Mar 2026 | Standalone | 3.17 | 3.17 | 0.0% | 2 Jun 2026 (opens in a new tab) | 7 Jul 2026 (opens in a new tab) |